Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Lymphangiogenesis and lymphatic metastasis in breast cancer.

Ran S, Volk L, Hall K, Flister MJ.

Pathophysiology. 2010 Sep;17(4):229-51. doi: 10.1016/j.pathophys.2009.11.003. Epub 2009 Dec 24.

2.

Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients.

Zhao YC, Ni XJ, Li Y, Dai M, Yuan ZX, Zhu YY, Luo CY.

World J Surg Oncol. 2012 Aug 20;10:165. doi: 10.1186/1477-7819-10-165.

3.

Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.

Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F.

Breast Cancer Res. 2011 Jun 21;13(3):R66. doi: 10.1186/bcr2903.

4.

Molecular control of lymphatic metastasis.

Achen MG, Stacker SA.

Ann N Y Acad Sci. 2008;1131:225-34. doi: 10.1196/annals.1413.020. Review.

PMID:
18519975
5.

Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.

He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K.

J Natl Cancer Inst. 2002 Jun 5;94(11):819-25.

PMID:
12048269
6.
7.

From tumor lymphangiogenesis to lymphvascular niche.

Hirakawa S.

Cancer Sci. 2009 Jun;100(6):983-9. doi: 10.1111/j.1349-7006.2009.01142.x. Epub 2009 Feb 20. Review.

8.

Tumor and lymph node lymphangiogenesis--impact on cancer metastasis.

Tobler NE, Detmar M.

J Leukoc Biol. 2006 Oct;80(4):691-6. Epub 2006 Jun 22. Review.

PMID:
16793912
9.

Induced lymphatic sinus hyperplasia in sentinel lymph nodes by VEGF-C as the earliest premetastatic indicator.

Liersch R, Hirakawa S, Berdel WE, Mesters RM, Detmar M.

Int J Oncol. 2012 Dec;41(6):2073-8. doi: 10.3892/ijo.2012.1665. Epub 2012 Oct 16.

10.

Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.

Liu H, Yang Y, Xiao J, Yang S, Liu Y, Kang W, Li X, Zhang F.

Microvasc Res. 2014 May;93:1-8. doi: 10.1016/j.mvr.2014.02.007. Epub 2014 Mar 3.

PMID:
24603190
11.

Pathways targeting tumor lymphangiogenesis.

Wissmann C, Detmar M.

Clin Cancer Res. 2006 Dec 1;12(23):6865-8. Review.

12.

Interaction of tumor cells and lymphatic vessels in cancer progression.

Alitalo A, Detmar M.

Oncogene. 2012 Oct 18;31(42):4499-508. doi: 10.1038/onc.2011.602. Epub 2011 Dec 19. Review.

PMID:
22179834
13.

Tumor-induced lymphangiogenesis: a target for cancer therapy?

Thiele W, Sleeman JP.

J Biotechnol. 2006 Jun 25;124(1):224-41. Epub 2006 Feb 23. Review.

PMID:
16497404
14.

IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma.

Zhao W, Wang J, Zhu B, Duan Y, Chen F, Nian W, Sun J, Zhang B, Tong Z, Chen Z.

Oncol Rep. 2016 Mar;35(3):1483-92. doi: 10.3892/or.2015.4516. Epub 2015 Dec 24.

PMID:
26706909
15.

Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.

Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Pickett B, Castro-Rivera E, Brekken RA, Gerard RD, Ran S.

Int J Cancer. 2007 Nov 15;121(10):2181-91.

16.
17.

Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.

He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K.

Cancer Res. 2005 Jun 1;65(11):4739-46.

18.

VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors.

Mattila MM, Ruohola JK, Karpanen T, Jackson DG, Alitalo K, Härkönen PL.

Int J Cancer. 2002 Apr 20;98(6):946-51.

19.

Lymphangiogenic growth factors, receptors and therapies.

Lohela M, Saaristo A, Veikkola T, Alitalo K.

Thromb Haemost. 2003 Aug;90(2):167-84. Review.

PMID:
12888864
20.

Supplemental Content

Support Center